https://www.selleckchem.com/products/odm208.html
prognostic factor for non-distant metastatic BC compared with either parameter alone and could easily be applied in clinical practice. The current standard of care for metastatic prostate cancer (mPCa) is androgen deprivation therapy (ADT) with or without anti-androgen and chemotherapy. The aim of this study was to evaluate the efficacy and safety of a multimodal approach including local primary tumor therapy, metastasis-directed therapy (MDT), and hormonal therapy in patients with oligometastatic prostate cancer (PCa). We reviewed data